Telesta Therapeutics Inc., formerly Bioniche Life Sciences Inc., is a Canada-based biopharmaceutical company. The Company is focused on the development, manufacturing, commercialization and licensing/acquisition of therapies for the global health market. The Company has developed the Mycobacterium phlei Cell Wall-Nucleic Acid Complex (MCNA) technology, a biologic immunotherapy or immunomodulator for the treatment of bladder cancer patients with high-risk non-muscle invasive bladder cancer who failed prior bacillus Calmette-Guerin (BCG) therapy. MCNA is a cell wall-nucleic acid composition prepared from the fractionation of a pure culture of Mycobacterium phlei. The Company has completed Phase III clinical trials for its MCNA product candidate. It is engaged in preparing for the commercial launch of MCNA in the United States. The Company's MCNA manufacturing site is located in Pointe Claire, Quebec. The Company has not generated any revenues from its operations.